The interplay between bile acids and mucosal adaptive immunity
Ahmed Dawood Mohammed,Ryan A. W. Ball,Jason L. Kubinak
DOI: https://doi.org/10.1371/journal.ppat.1011356
IF: 7.464
2023-06-23
PLoS Pathogens
Abstract:The fundamental role of the gut mucosal immune system is to maintain tolerance towards luminal antigens and this is achieved through a heavily coordinated and multilayered system of two-way interactions between gut-resident immune cells and molecular signals provided by the microbiome. Mucosal humoral immune responses (and primarily secretory IgA) are a major means by which the host regulates the taxonomic composition [1–7] spatial organization [8–10] and metabolic function of the microbiota [11–13]. One of the most important metabolic functions carried out by commensal microbes is biotransformation of host bile acids (BAs) [14]. BAs are host-derived amphipathic molecules that act as emulsifiers to promote the solubilization and absorption of dietary lipids and lipid-soluble vitamins [15]. BAs are mainly produced in the liver as primary BAs using cholesterol as a precursor and are then transported and stored in the gallbladder until being secreted into the duodenum postprandially. Approximately 95% of all BAs secreted into the gut will be reabsorbed in the distal ileum [16,17]. Under steady-state conditions, the 5% of BAs that escape this recycling process will reach the colon where they are modified by commensal gut bacteria to become secondary BAs. The gut microbiota modifies luminal BA biochemistry through different enzymatic reactions: deconjugation, dehydroxylation, dehydrogenation, epimerization, and oxidation-reduction. The first and rate-limiting step in bacterial BA biotransformation is the cleavage of glycine or taurine from BAs (deconjugation) and this is carried out by bacterial bile salt hydroxylase ( bsh ) enzymes. Bacterial deconjugation of BAs blocks the active transport of BAs through the apical sodium BA transporter (ASBT) [18]. Genetic studies of the human gut microbiota have revealed that members of all major bacterial phyla possess bsh genes and are capable of performing BA deconjugation [19,20]. In contrast to deconjugation, species within several families of the Firmicutes phylum (e.g., Lactobacillaceae, Clostridiaceae, Lachnospiraceae, Ruminococcaceae) appear to be primarily responsible for subsequent enzymatic reactions [21,22]. In addition, intestinal microbiota may regulate the synthesis of BAs in the liver through their ability to directly influence the balance of conjugated BAs in the lumen [23]. Micromolar shifts in the concentrations of hydrophobic BAs can stimulate enterocyte apoptosis [24,25], so enterohepatic circulation of BAs is a tightly regulated process operating through negative feedback mechanisms that maintain physiologically benign BA composition and concentrations. Recently, BAs have been described as signaling molecules that serve as ligands to the nuclear farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor (TGR5) [26]. In addition to their contributions to host metabolism, BAs are also emerging as critical regulators of mucosal immune responses [27–31] with implications in various disease states [32–34]. How BAs promote immune tolerance in the gut, and whether/how the adaptive immune system operates to reinforce this, is an important emerging area of research in mucosal immunology. This review seeks to provide a brief overview of the current state of our knowledge regarding the two-way interaction between BAs and adaptive immunity, with an emphasis on recent work supporting that adaptive (humoral) immunity may serve to reinforce BA-induced immunological tolerance.
microbiology,virology,parasitology